Genesys Diagnostics, INC.
Genesys Diagnostics, INC. was paid $1.44M by Medicaid between Feb 2018 and Aug 2023, across 36 billing codes. Its largest line is U0004, 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r — 52% of everything it billed.
33Billing provider infoGENESYS DIAGNOSTICS, INC.
NEW LONDON, CT 06320
NEW LONDON, CT 06320
33aNPI1932445681assigned 12/28/2012
33bProvider typeClinical Laboratory Director (Non-physician)
28Total paid$1.44M
24GClaims44,615
24DCodes billed36
24AFirst – last monthFeb 2018 – Aug 2023
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 565 | $58K | |
| 2019 | 1,449 | $125K | |
| 2020 | 10,975 | $390K | |
| 2021 | 20,728 | $563K | |
| 2022 | 7,932 | $236K | |
| 2023 | 2,966 | $72K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 52% | 12,463 | 8,940 | $748K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 12% | 8,162 | 6,251 | $170K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 10% | 1,968 | 1,463 | $150K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 10.0% | 537 | 468 | $144K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 3.6% | 2,125 | 1,519 | $51K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 2.2% | 775 | 714 | $32K |
| 81408 | 1.3% | 232 | 142 | $19K | |
| 87581 | 1.2% | 742 | 656 | $17K | |
| 87486 | 1.2% | 740 | 654 | $17K | |
| 87631 | 1.1% | 178 | 162 | $16K | |
| 87150 | <1% | 90 | 83 | $10K | |
| 81401 | <1% | 759 | 287 | $8K |
24 more codes
| 81226 | <1% | 82 | $7K | |
| 81407 | <1% | 180 | $6K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 5,788 | $5K |
| 81479 | Unlisted molecular pathology procedure | <1% | 906 | $5K |
| 81225 | <1% | 82 | $5K | |
| 81405 | <1% | 181 | $4K | |
| 81406 | <1% | 298 | $4K | |
| 87505 | <1% | 91 | $3K | |
| 81227 | <1% | 83 | $3K | |
| P9603 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled | <1% | 6,330 | $2K |
| 81210 | <1% | 203 | $2K | |
| 81241 | <1% | 100 | $2K | |
| G2024 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen source | <1% | 690 | $2K |
| 81240 | <1% | 100 | $2K | |
| 81443 | <1% | 15 | $2K | |
| 81355 | <1% | 83 | $1K | |
| 81328 | <1% | 180 | $1K | |
| 81291 | <1% | 82 | $1K | |
| 81329 | <1% | 15 | $980.92 | |
| 87500 | <1% | 91 | $898.24 | |
| 87653 | <1% | 90 | $870.17 | |
| 87640 | <1% | 90 | $870.17 | |
| 81161 | <1% | 15 | $758.88 | |
| 81229 | 0% | 69 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialAHUJA, DIVAKAR (CEO)